A5050216463- Hepatitis C virus research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Systemic Lupus Erythematosus Research
- Liver Diseases and Immunity
- Lung Cancer Treatments and Mutations
- COVID-19 Impact on Reproduction
- Renal Diseases and Glomerulopathies
- COVID-19 Clinical Research Studies
- Colorectal Cancer Treatments and Studies
- Dialysis and Renal Disease Management
- Inflammasome and immune disorders
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Hepatitis Viruses Studies and Epidemiology
- Metabolism and Genetic Disorders
- Complement system in diseases
- Cancer Mechanisms and Therapy
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Advanced biosensing and bioanalysis techniques
- RNA modifications and cancer
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
BIOCAD (Russia)
2012-2025
Abstract Objective and design The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy safety IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19. Subjects study included 217 patients. eligible were men non-pregnant women aged 18 years or older, hospitalized for COVID-19 pneumonia. Treatment 206 randomized (1:1) receive single subcutaneous administration LVL 324 mg placebo, both combination standard care (SOC). 204...
The search for new therapeutic options the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. article presents results double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on efficacy and safety divozilimab (BCD-132) SSc. Objective : to investigate patients with SSc compared placebo. Material methods . After enrolment study, received or placebo 48 weeks, after which they were switched open-label therapy until week 96. Results...
Background. In an era of breakthroughs in cancer immunotherapy, CheckMate 067 studies declared the combination PD-1 and CTLA-4 inhibitors a new standard care for patients with metastatic melanoma (MM). A significant limitation widespread use ipilimumab nivolumab routine clinical practice is high risk severe immune-mediated adverse events. Prolgolimab nurulimab are fixed doses original monoclonal antibodies (manufactured by JSC "BIOCAD," Russia) to receptor (prolgolimab) (nurulimab) (3:1...
Prolgolimab is the first Russian PD-1 inhibitor approved for first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. It was in two weight-based regimens 1 mg/kg Q2W 3 Q3W, but because re-evaluation dosing paradigm, studying a fixed-dose regimen considered perspective.
Aim. To establish the equivalent efficacy and comparable safety profile of biosimilar Acveris referent eculizumab product Soliris used for treatment paroxysmal nocturnal hemoglobinuria (PNH). Materials methods. Were included in phase III multicenter 28 PNH patients, open-label clinical trial. Participants were randomized (1:1) into 2 groups: investigational (Acveris, n=14) (Soliris, n=14). Patients received as intravenous infusion 600 mg once a week during first 4 weeks, 900 at 5 then every...